Skip to search formSkip to main contentSkip to account menu

AT 877

Known as: AT-877, AT877 
National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

Isoquinolinesfasudil

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2005
2005
Dose escalation trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid haemorrhage
SummaryThe initial dose-escalating clinical trial of a novel calcium antagonist, AT877, in patients with aneurysmal subarachnoid… 
Review
2001
Review
2001
Effect of Fasudil HCl, a protein kinase inhibitor, on cerebral vasospasm.
Fasudil HCl (HA1077, AT877, Eril) was first introduced as a unique vasodilator and intracellular calcium antagonist. It dilated… 
1993
1993
AT‐877, a Ca2+ antagonist, fails to reduce infarct size following rat middle‐cerebral artery occlusion
We investigated the effects of AT‐877, a Ca2+ antagonist, on rat middle‐cerebral artery occlusion. All rats had 6‐h ischemia, and… 
Review
1990
Review
1990
New pharmacological strategies in vascular diseases: a novel intracellular calcium antagonist, HA1077 (AT-877) and cerebral vasospasm.
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)